Santhera’s AGAMREE Shows Promising Anti-Inflammatory Profile in Phase 1 Study
Event summary
- Santhera notes topline results from Catalyst’s Phase 1 study of AGAMREE®, showing glucocorticoid and anti-inflammatory activity without significant immunosuppressive effects.
- Study conducted in healthy adult volunteers demonstrated equipotency between deflazacort and AGAMREE® with less pronounced immunosuppressive biomarker effects.
- Catalyst holds North American commercialization rights to AGAMREE® under a 2023 license agreement, with Santhera eligible for sales-based milestone payments and royalties.
The big picture
Santhera’s AGAMREE® is positioned as a next-generation dissociative corticosteroid, offering anti-inflammatory benefits with reduced systemic side effects. The Phase 1 data supports its potential for broader use in chronic inflammatory rare diseases, aligning with the growing demand for safer, more targeted therapies in this space. Catalyst’s commercialization efforts could further validate AGAMREE®’s market potential beyond Duchenne muscular dystrophy (DMD).
What we're watching
- Commercialization Strategy
- How Catalyst will leverage these results to expand AGAMREE®’s market reach in North America and whether Santhera can secure similar partnerships for other regions.
- Regulatory Pathways
- The pace at which additional indications for AGAMREE® could be approved, given its differentiated safety profile.
- Revenue Potential
- Whether the sales-based milestone payments and royalties from Catalyst will significantly impact Santhera’s financial performance.
Related topics